Cocrystal Pharma price target lowered to $35 from $42 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cocrystal Pharma to $35 from $42 and keeps a Buy rating on the shares. Last month, Cocrystal reported "highly favorable" safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study, the analyst tells investors in a research note. The firm sees a "substantial market opportunity" in the influenza space for the company.